Across its top 20 institutional holders, BTAI's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 10/100, avg. turnover score 30/100).

Quarterly Activity

Recent Activity

+$6.0M

Total Buy Value

$940.3K

Total Sell Value

New buy5

Trim8

Add9

Sold out9

Net Buyers

Net Sellers

Smart Money Convergence

BTAI does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-03-31 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-07-06

2026-07-06

BioXcel Therapeutics (BTAI) entered a short-term amendment with its lenders on July 3rd to avoid an immediate default. The deal defers a ~$9M payment from June 30th to July 31st and cuts the minimum cash covenant to $7.5M. In exchange, the company must secure a transaction repaying all loans by July 31st. A lender-approved director now leads a special board committee with sole authority over a sale or restructuring. Executive compensation and hiring are frozen.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

CUSIP

09075P204

FAQ

Who are the top institutional investors holding BIOXCEL THERAPEUTICS INC (BTAI)?

Major stakeholders currently include Millennium Management LLC ($2.6M), Armistice Capital, LLC ($2.6M), Oaktree Capital Management LP ($323.2K). Based on the latest 13F filings, there are a total of 39 tracked investment funds and institutions maintaining positions in BTAI.

What is the overall institutional sentiment toward BTAI recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $1.6M, driven by 14 managers accumulating shares while 17 reduced their exposure.

Which institutions have been selling or reducing their BTAI positions?

In the latest period, 8 funds trimmed their holdings, and 9 managers completely exited their positions. The aggregate reported sell value was $940.3K.

Are there any notable investors adding BTAI to their portfolios?

Yes, buying activity remains notable. 5 institutions opened new positions in {ticker}, and 9 existing holders added to their shares. The total reported buy value for the quarter amounted to $6.0M.